Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Merck
Johnson and Johnson
Dow
Harvard Business School

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IDAMYCIN

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Idamycin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002812 ↗ Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia Completed National Cancer Institute (NCI) Phase 3 1996-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
NCT00002812 ↗ Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia Completed Children's Oncology Group Phase 3 1996-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
NCT00002816 ↗ Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia Completed National Cancer Institute (NCI) Phase 3 1996-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
NCT00002816 ↗ Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia Completed Children's Oncology Group Phase 3 1996-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Idamycin

Condition Name

Condition Name for Idamycin
Intervention Trials
Leukemia 14
Acute Myeloid Leukemia 8
Untreated Adult Acute Myeloid Leukemia 5
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Idamycin
Intervention Trials
Leukemia 29
Leukemia, Myeloid 22
Leukemia, Myeloid, Acute 21
Myelodysplastic Syndromes 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Idamycin

Trials by Country

Trials by Country for Idamycin
Location Trials
United States 178
Canada 15
Australia 7
Netherlands 2
Switzerland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Idamycin
Location Trials
Texas 19
California 10
Missouri 7
North Carolina 6
New York 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Idamycin

Clinical Trial Phase

Clinical Trial Phase for Idamycin
Clinical Trial Phase Trials
Phase 3 3
Phase 2 15
Phase 1/Phase 2 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Idamycin
Clinical Trial Phase Trials
Completed 20
Withdrawn 3
Recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Idamycin

Sponsor Name

Sponsor Name for Idamycin
Sponsor Trials
National Cancer Institute (NCI) 16
M.D. Anderson Cancer Center 14
Children's Oncology Group 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Idamycin
Sponsor Trials
Other 25
NIH 16
Industry 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Moodys
Express Scripts
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.